Q32 Bio

Q32 Bio CROIC

The Cash Return on Invested Capital (CROIC) of Q32 Bio (QTTB) as of Oct 31, 2026 is -362.90 %. In the previous year, Cash Return on Invested Capital (CROIC) was -132.15 % — a change of 174.61% (lower).

CROIC

-362.90 %

YoY

174.61%

Last updated:

Cash Return on Invested Capital (CROIC) of Q32 Bio is 2024 -362.90 % . Cash Return on Invested Capital (CROIC) of Q32 Bio was 2023 -132.15 % . It decreases by 174.61% lower compared to the previous year.

The Q32 Bio CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2017
4.60 USD
Jan 1, 2018
-34.37 USD
Jan 1, 2019
-43.79 USD
Jan 1, 2020
-50.03 USD
Jan 1, 2021
-66.09 USD
Jan 1, 2022
-64.58 USD
Jan 1, 2023
-132.15 USD
Jan 1, 2024
-362.90 USD
The Q32 Bio CROIC history
YEARCROICYoY
-362.90 %+174.61%
-132.15 %+104.64%
-64.58 %-2.28%
-66.09 %+32.09%
-50.03 %+14.26%
-43.79 %+27.40%
-34.37 %-847.44%
4.60 %-103.29%
-139.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q32 Bio Stock analysis

What does Q32 Bio do? Homology Medicines, Inc. generates revenue by developing and commercializing treatments for rare diseases at the genetic level. The company operates as a technology platform focused on creating a pipeline of new medicines that address and cure the underlying cause of monogenic diseases. Its lead product candidate, HMI-102, is a gene therapy designed for the treatment of phenylketonuria (PKU), with the PKU program specifically targeting adults using this gene therapy approach. The firm utilizes its suite of 15 adeno-associated virus vectors (AAVHSCs) to enable a method of gene editing called gene correction, allowing for precise targeting of disease-relevant tissues across both gene editing and gene therapy modalities. Q32 Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q32 Bio stock

Cash Return on Invested Capital (CROIC) of Q32 Bio is -362.90 % in 2024.

Cash Return on Invested Capital (CROIC) of Q32 Bio changed from -132.15 % to -362.90 %, representing a 174.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Q32 Bio since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Q32 Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Q32 Bio

All Key Metrics — Q32 Bio